Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

#LiverResearch

Home » #LiverResearch
AASLD 2024: Dr. Mingqin Lu’s Team Presents Study on Biomimetic Exosomes Loaded with Iridium Nanozyme for Acute Liver Failure Treatment

AASLD 2024: Dr. Mingqin Lu’s Team Presents Study on Biomimetic Exosomes Loaded with Iridium Nanozyme for Acute Liver Failure Treatment

Posted by By Mourabit Halima 2024.12.17
At the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, Professor Mingqin Lu’s team from The First Affiliated Hospital of Wenzhou Medical University unveiled their latest…
Read More
AASLD 2024丨Dr. Xiaohong Gao: Initiating TDF at Different Gestational Weeks Safely Prevents HBV Mother-to-Child Transmission

AASLD 2024丨Dr. Xiaohong Gao: Initiating TDF at Different Gestational Weeks Safely Prevents HBV Mother-to-Child Transmission

Posted by By Lisa Cui 2024.12.06
Despite extensive research, there remains no universal consensus on the optimal timing for initiating antiviral therapy during pregnancy to prevent hepatitis B virus (HBV) mother-to-child transmission (MTCT). Divergent recommendations have…
Read More
AASLD’s Chinese Impact: Dr. Liang Peng’s Team Achieves Multiple Research Milestones in Chronic Hepatitis B and Related Liver Failure

AASLD’s Chinese Impact: Dr. Liang Peng’s Team Achieves Multiple Research Milestones in Chronic Hepatitis B and Related Liver Failure

Posted by By El Bachir MOURABIT 2024.12.03
From November 15-19, 2024, the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) was held in San Diego, USA. At this prestigious event, Dr.…
Read More
Dr. Wai-Kay Seto’s team: Multiple Studies on Hepatic Diseases Management with New Hepatitis B Drugs, Fatty Liver Monitoring, and Liver Cancer Risk Factors

Dr. Wai-Kay Seto’s team: Multiple Studies on Hepatic Diseases Management with New Hepatitis B Drugs, Fatty Liver Monitoring, and Liver Cancer Risk Factors

Posted by By Lisa Cui 2024.01.14
The 58th Annual Meeting of the European Association for the Study of the Liver (EASL2023) and the EASL Congress 2023 have come to a close. During this conference, Dr. Wai-Kay…
Read More
Seven Achievements from Peking University Hepatology Institute Shine at EASL 2023

Seven Achievements from Peking University Hepatology Institute Shine at EASL 2023

Posted by By Mourabit Halima 2023.12.25
From June 21st to 24th, the annual international liver disease conference, the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and EASL Congress…
Read More
Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B

Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B

Posted by By Peter W. PENG 2023.12.21
Chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) are both significant contributors to liver-related complications and mortality. Dr. Youwen Tan's team at the Third People's Hospital of Jiangsu…
Read More
Recent Posts
  • Getting to the Bottom of the Debate 2.0 | Metastatic Renal Cell Carcinoma: Extrapolating Second-Line Evidence and Individualizing First-Line Dual Immunotherapy Versus Immunotherapy–TKI Combinations—A Debate Between Professors Xuewen Jiang and Hailiang Zhang
  • Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou
  • Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits
  • 2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma
  • Professor Olive Daniel: From Basic Research to Clinical Treatment — Translational Pathways in Immune Regulation and Prospects for China-France Collaboration | 2026 China-France Scientific Symposium on Hematology and Immunology
Recent Comments
    Archives
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top